Irbesartan, Sparsentan Treatment Demonstrate Significantly Slower Kidney Function Decline Compared with SoC
A matching-adjusted indirect comparison (MAIC) revealed patients with immunoglobulin A nephropathy (IgAN) treated with either sparsentan or maximally tolerated irbesartan experienced significantly slower declines in kidney function compared with standard …